N. Aaronson/F. Calais da Silva: Prospects for the future - quality of life evaluation in prostatic cancer protocols. Progr. Clinical Biological Research 243 B (1987), 501-512. 20888 Per-Anders Abrahamsson: Prostate cancer - to treat or not to treat? Europ. Urology Suppl. 8 (2009), 418-423. 9442 Koichiro Akakura a.o.: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Internet, ca. 1996. 9010 Duke Bahn: hormonal deprivation therapy for prostate cancer. Internet 1996. 20369 C. Bangma/S. Roemeling/F. Schröder: Overdiagnosis and overtreatment of early detected prostate cancer. World J. Urol. 25 (2007), 3-9. 9386 Israel Barken: The decision pyramid. Internet 1996. 18610 P. Belik/P. Dayananda/John Kemper/Mikhail Shvartsman: A stochastic model for PSA levels - behavior of solutions and population statistics. J. Math. Biol. 53 (2006), 437-463. Investigates a stochastic model for the PSA levels following radiotherapy. 19858 James Bicher/Ralph Wolfstein/Boris Burmistrovich/Tressia Keen: Thermoradiotherapy for prostate cancer. Internet 2007, 2p. 16483 Martin Boeckh: Mit Ultraschall gegen Krebs. Spektrum 2003/4, 98-99. Therapie von Prostatakrebs mit hochfokussiertem Ultraschall. M. Bolla a.o.: Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the EORTC radiotherapy and genitourinary tract cancer cooperative groups. Proc. Am. Soc. Clin. Oncol. 15 (1996), 238-... A. Keith Brewer: High pH therapy for cancer tests on mice and humans. Pharmacology Biochem. & Behavior 31, suppl. 1 (1984), 1-6. 9441 Nicholas Bruchovsky a.o.: Control of [prostate] tumor progression by maintenance of apoptosis. Internet, ca. 1996. 8933 Bill Buckman: Taking charge of your own case. Internet, ca. 1995. [Archiv] R. Cespedes/L. Pisters/A. von Eschenbach/E. McGuire: Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of prostate - results in 143 patients. J. Urology January 1997, ... P. Chang a.o.: Use of transurethral prostatectomy clinical path to monitor health outcomes. J. Urology January 1997, ... 9016 L. Cleeve/J. Goad: The role of hormone therapy in the management of prostate cancer. Australian Prostate Cancer Forum 19/1 (1995), ... B. Corn a.o.: Conformal treatment of prostate cancer with improved targeting - superior prostate-specific antigen response compared to standard treatment. Int. J. Radiat. Oncol. Biol. Phys. 32/2 (1995), 325-330. 9378 Romano Danesi/William Figg/Eddie Reed/Charles Myers: Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in pc-3 human prostate cancer cells. Internet 1995. Louis Denis (ed.): Antiandrogens in prostate cancer. Springer 1996. 3-540-60599-1. DM 118. J. Fowler/F. Terrell/D. Renfroe: Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J. Urology November 1996, ... 6531 Marc Garnick: Das Behandlungsdilemma bei Prostatakrebs. Spektrum 1994/6, 38-47. Goldenberg a.o.: A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 month post-treatment PSA results. J. Urol. April 1997, ... Cyproterone acetate (a steroidal antiandrogen) was used for 12 weeks prior to RP in selected patients. Positive margins were significantly reduced by its use, but PSA progression at 2 years was not statistically affected. 19851 Miles Goldstraw/R. Kirby: The case for radical prostatectomy. Ann. R. Coll. Surg. Engl. 88 (2006), 439-442. 16540 Michael Groß: DNA-Computer zur Krebsdiagnose und -therapie. Spektrum 2004/9, 23-24. Ein raffiniert konstruiertes DNA-Molekül kann vier Indikatoren für Prostatakrebs testen und bei positivem Ergebnis eine tumorhemmende Substanz freisetzen. Noch nicht einsatzreif. 21177 Xiao Hu: Optimization of cancer chemotherapy - local delivery of paclitaxel and pharmacokinetics of suramin. PhD thesis Ohio State Univ. 2004, 181p. 9373 Gary Huckabay: Money [questions in prostate cancer treatment]. Internet 1997. G. Hudes a.o.: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncology 10/11 (1992), 1754-1761. 20302 Gina Kolata: New take on a prostate drug, and a new debate. New York Times Online 15 June 2008, 3p. Finasteride as prostate cancer prevention? 9376 Fernand Labrie a.o.: Combination of screening and preoperative endocrine therapy: The potential for an important decrease in prostate cancer mortality. Internet 1996. Fernand Labrie: Prostate cancer - recent advances in diagnosis and treatment. Blackwell 1997. 1-89809911-1. $40. Fernand Labrie: Androgens and prostate cancer. CRC 1997. 0-84935824-8. $139. 19852 Stephen Langley: Permanent low-dose rate prostate brachytherapy. Ann. R. Coll. Surg. Engl. 88 (2006), 442-444. [19851] 8992 Robert Leibowitz: December 1993. Internet 1993. 8988 Robert Leibowitz: Letters to Patrick Walsh. Internet 1994. James Lewis/E. Roy Berger/James Lewis: New guidelines for diagnosing and treating prostate cancer. Health Education Literary Publisher 1997, 0-91525347-X. $23. 8993 Shutsung Liao: The development of hormone independent disease: Is there a chance for a cure? Internet 1995. 8860 Kristen Lidke Finn: Planting seeds of progress against prostate disease. Advance Summer 1995, 6-8, 10, 12-13. About John Oesterling. Sylvan Meyer/Seymour Nash: Prostate cancer. Making survival decisions. Chicago UP. J. Mokulis/I. Thompson: Radical prostatectomy - is perineal approach more difficult to learn? J. Urology January 1997, ... L. Montie: Significance and treatment of positive margins or seminal vesicle invasion after radical prostatectomy. Urol. Clin. North Am. 17 (1990), 803-812. 8934 Bart Moran: Watchful waiting. Internet, ca. 1995. [Archiv] Judd Moul: Radical prostatectomy and cryotherapy - answers, more questions. J. Urology January 1997, ... 9042 Judd Moul/Walter Reed: Hormonal therapy for prostate cancer. Internet, ca. 1996. 21578 Claire Morgan/.../Robert Leonard: The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol. 46 (2007), 669-677. D. Newling (ed.): Prostate cancer - hormonal treatment and treatment of advanced disease. Karger 1994. 3-8055-6111-3. DM 30. 20889 Jean de la Rosette/Vladimir Mouraviev/Thomas Polascik: Focal targeted therapy will be a future treatment modality for early stage prostate cancer. Europ. Urology Suppl. 8 (2009), 424-432. G. Onik/B. Rubinsky/G. Watson/Richard Ablin (ed.): Percutaneous prostate cryoablation. Quality Medical Publishing 1995. Kenneth Pienta: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncology 12/10 (1994), 2005-2012. 9316 Edward Piepmeier: Firsthand account of suramin therapy. Internet 1996. Pisters a.o.: The efficacy and complications of salvage cryotherapy of the prostate. J. Urol. 157 (1997), 921-925. Haakon Ragde/Benjamin Tjoa: Development of a new prostate cancer vaccine. Ca. 1996. A. Rana a.o.: A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Europ. J. Cancer 31 A/6 (1995), 871-875. "The present study was undertaken mainly to investigate whether prolactin manipulation combined with maximal androgen blockage improves the effectiveness of treatment in advanced prostatic cancer." (Abstract) M. Roach a.o.: Radiotherapy for high grade clinically localized adenocarcinoma of prostate. J. Urology November 1996, ... S. Schild a.o.: Use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J. Urology November 1996, ... P. Smith: The case for no initial treatment of localized prostate cancer. Urologic Clin. North Am. 17 (1990), 827-834. R. Stephenson/R. Middleton/T. Abbott: Wide excision (nonnerve sparing) radical retropubic prostatectomy using initial perirectal dissection. J. Urology January 1997, ... 9036 Stephen Strum: Brachytherapy. Internet, ca. 1996. 9023 Stephen Strum/Robert Leibowitz/Steven Koehler: Small cell carcinoma of the prostate (SCPC) - complete response to cyclophosphamide, doxorubicin and etoposide (CDE). Internet, ca. 1995. 9024 Stephen Strum/Mark Scholz: New approaches in prostate cancer 1994-1996. Patients with early disease I. Internet 1996. 9025 Stephen Strum/Mark Scholz: New approaches in prostate cancer 1994-1996. Patients with early disease II. Internet 1996. 9375 Stephen Strum/Mark Scholz: Brachytherapy - implantation of prostate cancer with radioactive isotopes analysis of the Seattle experience. Internet 1996. Stephen Strum/Glenn Tisman: Anemia of androgen deprivation (AAD) in patients receiving combination hormonal blockade - response to erythropoietin. Proc. Am. Soc. Clin. Oncol. 13 (1994), 238-... Stephen B. Strum, & Glenn Tisman, B. Tabet/S. Levine: Nerve block in prostate surgery. J. Urology November 1996, ... 19784 John Toon: [Mathematics and brachytherapy planning in prostate cancer.] Internet 2001, 2p. 8930 Earl Ubell: What is the best way to treat prostate cancer? Parade Magazine 3 March 1996, 8. [Archiv] 19991 John Vig: [On diagnosis and treatment options.] Internet YANA 2007, 5p. J. Vukanovic/J. Isaacs: Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res. 55/16 (1995), 3517-3520. Patrick Walsh: Radical prostatectomy, preservation of sexual function, cancer control - the controversy. Urol. Clin. North America 14 (1987), 663-673. Patrick Walsh a.o.: Long-term results of radiation therapy for isolated PSA elevations following radical prostatectomy. J. Urol. April 1997, ... Their data indicate that men who had a PSA recurrence during the first year after surgery, those with Gleason score of 8 or above, and those with positive SV or lymph nodes rarely benefitted from XRT to the prostatic bed. Men who had a delayed PSA increase, Gleason score of 7 or less, and negative SV and lymph nodes responded better. The longer the delay to PSA increase the better the response. If 3 years or longer, 26% responded. If 5 years or longer, 45% responded. Men were followed for at least 2 years after XRT, and detectable PSA looks like the failure criterion, but I'm not sure from the abstract. 15468 Ronald Wheeler: Prostate cancer treatment - too many radicals, too many failures. Internet [www.theprostatcenter.com] 2000, 6p. Thomas Wiegel/Wolfgang Hinkelbein/K. Miller: Controversies in uro-oncology. Karger 2002. Eur 133. Important, but expensive. J. Ward a.o.: Malignant cytological washings from radical prostatectomy specimens: possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease. J. Urology October 1996, ... 8941 Pete Wilson: Cured? Neoadjuvant CHT and RP. Internet 1995. [Archiv] 8932 ZZ. Alternative treatments and the power of attitude. A patient's story. Internet 1994. [Archiv] 8929 ZZ. Virtual anatomical radical prostatectomy. Internet, ca. 1995 [Archiv] 8942 ZZ. Prostate cancer therapies. Internet, ca. 1995. [Archiv] ZZ. Current topics in prostate cancer treatment. Karger 1996, 28p. 3-8055-6312-4. DM 30. 9344 ZZ: The treatment of advanced disease. Internet 1995. 9353 ZZ: Interventions and treatments for prostate cancer. Internet 1996. 9346 ZZ: The treatment of prostate cancer - an overview. Internet 1996. 9343 ZZ: Interventions for terminal illness. Internet 1996. 9320 ZZ: Interventions for early stage disease. Internet 1996. 9323 ZZ: Interventions in late stage disease. Internet 1996. 9324 ZZ: NCI/PDQ Prostate cancer treatment for physicians. Internet 1997. 20368 ZZ: Die Behandlung des lokal begrenzten Prostatakrebses. Univ.-Klinik Urologie Innsbruck ca. 2005, 13p.